At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed non-small cell lung cancer (NSCLC)
- ✓At least 1 bidimensionally measurable brain metastasis confirmed by MRI within past 2 weeks
- ✓Not eligible for surgical resection or radiosurgery of brain metastasis
- ✓Systemic disease not in immediate need of chemotherapy
- ✕HIV positive or AIDS-related illness
- ✕Prior temozolomide
- ✕Prior radiotherapy to the brain, including stereotactic radiosurgery to a different lesion
- ✕Concurrent intensity modulated radiotherapy or 3-D cranial radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Temozolomide and Radiation therapy for Lung Cancer and Metastatic Cancer. Completed, enrolled 26 participants.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as temozolomide may make the tumor cells more sensitive to radiation therapy. Combining temozolomide with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with whole-brain radiation therapy works in treating patients with brain metastasis secondary to non-small cell lung cancer.
Study Details
Timeline
Interventions
Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
Standard whole brain radiation therapy 30 Gy in ten fractions.